Nan Fung Group Holdings Ltd
13F Reported Value
ⓘ$131.5M
Holdings
25
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Nan Fung Group Holdings Ltd disclosed 25 positions worth $131.5M in its Form 13F-HR for Q2 2026, led by $MPLT (MapLight Therapeutics, Inc.) at 26.5% of the equity portfolio, followed by $LBRX and $EVMN. During the quarter the fund opened 1 new position and exited 0 — including a new stake in $CHYM. The portfolio is most concentrated in Healthcare (97.2% of disclosed assets). All figures are sourced directly from Nan Fung Group Holdings Ltd’s Form 13F-HR filing with the SEC under CIK 1782539.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- —
Quality
$34.8M971,253 sh - —
Quality
$20.5M630,657 sh - 14.9#2,860
Quality
$19.2M1,441,032 sh - —
Quality
$6.5M987,222 sh - 77.4
Quality
$6.1M53,742 sh - 33.9
Quality
$5.5M49,120 sh - —
Quality
$4.5M15,722 sh - —
Quality
$4.2M300,565 sh - 44.8
Quality
$3.6M13,600 sh - —
Quality
$3.6M19,253 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 MapLight Therapeutics, Inc.$MPLT | — | $34.8M | 971,253 |
 LB PHARMACEUTICALS INC$LBRX | — | $20.5M | 630,657 |
 Evommune, Inc.$EVMN | 14.9#2,860 | $19.2M | 1,441,032 |
 CYBIN INC.$HELP | — | $6.5M | 987,222 |
 INCYTE CORP$INCY | 77.4 | $6.1M | 53,742 |
 RHYTHM PHARMACEUTICALS, INC.$RYTM | 33.9 | $5.5M | 49,120 |
 BeOne Medicines Ltd.$ONC | — | $4.5M | 15,722 |
 Oculis Holding AG$OCS | — | $4.2M | 300,565 |
 Ascendis Pharma A/S$ASND | 44.8 | $3.6M | 13,600 |
 Revolution Medicines, Inc.$RVMD | — | $3.6M | 19,253 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Nan Fung Group Holdings Ltd's 25 positions.
Showing top 10 of 25 holdings.
Sector Allocation
Healthcare
$127.8M
Technology
$2.2M
Financials
$1.6M
Full Holdings — Nan Fung Group Holdings Ltd (Q2 2026)
All 25 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $MPLT | MapLight Therapeutics, Inc. | $34.8M | 26.5% | +0% | — |
| 2 | $LBRX | LB PHARMACEUTICALS INC | $20.5M | 15.6% | +0% | — |
| 3 | $EVMN | Evommune, Inc. | $19.2M | 14.6% | +0% | 14.9 |
| 4 | $HELP | CYBIN INC. | $6.5M | 5.0% | +115% | — |
| 5 | $INCY | INCYTE CORP | $6.1M | 4.6% | +0% | 77.4 |
| 6 | $RYTM | RHYTHM PHARMACEUTICALS, INC. | $5.5M | 4.2% | +0% | 33.9 |
| 7 | $ONC | BeOne Medicines Ltd. | $4.5M | 3.4% | +0% | — |
| 8 | $OCS | Oculis Holding AG | $4.2M | 3.2% | -14% | — |
| 9 | $ASND | Ascendis Pharma A/S | $3.6M | 2.8% | +0% | 44.8 |
| 10 | $RVMD | Revolution Medicines, Inc. | $3.6M | 2.7% | +0% | — |
| 11 |  $KYMR | Kymera Therapeutics, Inc. | $3.5M | 2.7% | +0% | 28.4 |
| 12 |  $MDGL | MADRIGAL PHARMACEUTICALS, INC. | $3.0M | 2.3% | +0% | 40.7 |
| 13 |  $CELC | Celcuity Inc. | $3.0M | 2.3% | +0% | — |
| 14 |  $ACAD | ACADIA PHARMACEUTICALS INC | $2.6M | 2.0% | +0% | 67.8 |
| 15 |  $ARGX | ARGENX SE | $2.6M | 2.0% | +0% | — |
| 16 |  $RXRX | RECURSION PHARMACEUTICALS, INC. | $2.2M | 1.7% | +0% | 23.3 |
| 17 |  $PCOR | PROCORE TECHNOLOGIES, INC. | $2.2M | 1.6% | +0% | 59.4 |
| 18 |  $HRMY | Harmony Biosciences Holdings, Inc. | $984,854 | 0.8% | +0% | 71.4 |
| 19 |  $INSM | INSMED Inc | $701,560 | 0.5% | +0% | 39.4 |
| 20 |  $ETHA | iShares Ethereum Trust ETF | $601,028 | 0.5% | +0% | — |
| 21 |  $IBIT | iShares Bitcoin Trust ETF | $531,575 | 0.4% | +0% | — |
| 22 |  $CHYM | Chime Financial, Inc. | $431,616 | 0.3% | NEW | 53.5 |
| 23 |  $RANI | Rani Therapeutics Holdings, Inc. | $375,321 | 0.3% | +0% | — |
| 24 |  $TRDA | Entrada Therapeutics, Inc. | $361,244 | 0.3% | +0% | 7.3 |
| 25 |  $BOLT | Bolt Biotherapeutics, Inc. | $19,250 | 0.0% | -83% | — |
New Positions (1)
$CHYM Chime Financial, Inc.$431,616Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Nan Fung Group Holdings Ltd including:
Track Nan Fung Group Holdings Ltd's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Nan Fung Group Holdings Ltd and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Nan Fung Group Holdings Ltd
13F Pro is an AI hedge fund tracker and stock research platform. For Nan Fung Group Holdings Ltd (SEC CIK: 1782539), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Nan Fung Group Holdings Ltd's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.